Shared on15 Jul 25Fair value Decreased 13%
The reduced analyst price target for NATCO Pharma reflects downgraded revenue growth forecasts and a lower future P/E, resulting in a fair value revision from ₹1133 to ₹972.09. What's in the News Board meeting scheduled to consider and approve audited financial results for the quarter and year ended March 31, 2025, as well as other business matters.
Shared on01 May 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on23 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 3.43%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25Fair value Decreased 4.67%
AnalystConsensusTarget has increased revenue growth from -6.7% to -7.5%.
Shared on19 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on12 Mar 25Fair value Increased 19%
AnalystConsensusTarget has decreased revenue growth from 0.5% to -6.7%, decreased profit margin from 29.0% to 20.4% and increased future PE multiple from 25.4x to 41.3x.